Podcast


Presenter: Dr. Michael Allan James McCormack BSc(Pharm) PharmD Samantha Moe PharmD

In episode 593, Mike and James invite Samantha Moe back to talk about a newer agent for osteoporosis. So, if you want to know all the evidence for romosozumab, tune in and all will be revealed about the benefits and harms. Show notes 1) Tools for Practice Tony Romo-sozumab: Winning touchdown in osteoporosis or interception…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here



CFPCLearn Logo

Listening to the Podcast can earn you MainPro+ Credits

Join Now

Already a CFPCLearn Member? Log in



Latest Podcasts

BS Medicine Episode #597: Insomnia – hours of sleep is not the goal!

In episode 597, James and Mike invite David Gardner to talk in depth about the issue of insomnia. We talk about triggers, precipitating factors, acute and chronic insomnia, and chronic…
Listen 0.5 credits available

BS Medicine Episode #596: PREMIUM – A painful podcast about methotrexate and walking for pain

In episode 596, Mike and James talk in a PREMIUM way about three trials that used methotrexate for osteoarthritis and walking for back pain. Nothing miraculous but there seems to…
Listen 0.5 credits available

BS Medicine Episode #595: How to slow the flow: Combined oral contraceptives

In episode 595, Mike and James invite Jennifer Young back to talk about the use of combined oral contraceptives for heavy menstrual bleeding (benign etiology) and see if they improve…
Listen 0.5 credits available

Presenter(s):

Dr. Michael Allan James McCormack BSc(Pharm) PharmD Samantha Moe PharmD

This content is certified for MainPro+ Credits, log in to access


Presenter(s):

  • Dr. Michael Allan
  • James McCormack BSc(Pharm) PharmD
  • Samantha Moe PharmD

Spearkers do not have any conflicts of interest to declare.